Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms [Internet] - PubMed

Review

Affiliations

• PMID: 24278999
• Bookshelf ID: NBK169524

Free Books & Documents

Review

Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms [Internet]

Kasandra Gauthier et al.

Free Books & Documents

Excerpt

Osteoporosis is a skeletal disorder characterized by compromised bone strength, predisposing patients to an increased risk of fracture. The postmenopausal form of osteoporosis affects more than 1.5 million Canadians, with prevalence increasing from 6% of women aged 50 to 59 years to more than 40% of women aged 80 years and older. Consequences of sustaining a fracture may be serious and include increased risk of subsequent fractures, hospitalization or institutionalization, decreased quality of life, and premature mortality, with a related burden on the health care system. Antiresorptive agents such as oral bisphosphonates are the standard treatment for postmenopausal osteoporosis, in conjunction with non-pharmacologic measures. Other treatment options include an intravenous bisphosphonate (zoledronic acid), a monoclonal antibody (denosumab), a bone-forming agent (teriparatide), and a selective estrogen receptor modulator (raloxifene). This systematic review was undertaken following a request from provincial drug formularies to evaluate the clinical effectiveness and harms of three of these agents, denosumab, raloxifene, and zoledronic acid, in postmenopausal women with osteoporosis. The evidence gathered is expected to clarify uncertainty regarding these agents and to inform policy-making in the population of interest.

Sections

• ACRONYMS AND ABBREVIATIONS
• EXECUTIVE SUMMARY
• 1. CONTEXT AND POLICY ISSUES
• 2. RESEARCH QUESTION
• 3. KEY MESSAGE
• 4. METHODS
• 5. RESULTS
• 6. DISCUSSION
• 7. CONCLUSIONS AND IMPLICATIONS FOR DECISION- OR POLICY-MAKING
• REFERENCES
• APPENDIX 1 LITERATURE SEARCH STRATEGY
• APPENDIX 2 SELECTION OF INCLUDED STUDIES
• APPENDIX 3 SUMMARY OF STUDY CHARACTERISTICS OF INCLUDED STUDIES
• APPENDIX 4 SUMMARY OF RELEVANT PATIENT POPULATION AND BASELINE CHARACTERISTICS
• APPENDIX 5 CRITICAL APPRAISAL OF INDIVIDUAL STUDIES

Similar articles

• Management of postmenopausal osteoporosis and the prevention of fractures.

  Gambacciani M, Levancini M. Gambacciani M, et al. Panminerva Med. 2014 Jun;56(2):115-31. Epub 2014 Jun 19. Panminerva Med. 2014. PMID: 24942322

• Denosumab (Prolia): Treatment to Increase Bone Mass in Men with Osteoporosis at High Risk for Fracture; or Who Have Failed or are Intolerant to Other Available Osteoporosis Therapy [Internet].

  [No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Oct. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Oct. PMID: 26962604 Free Books & Documents. Review.

• Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.

  Miller RG. Miller RG. Geriatrics. 2006 Jan;61(1):24-30. Geriatrics. 2006. PMID: 16405361 Review.

• Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.

  Josse R, Khan A, Ngui D, Shapiro M. Josse R, et al. Curr Med Res Opin. 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Epub 2013 Jan 25. Curr Med Res Opin. 2013. PMID: 23297819 Review.

Publication types

Grants and funding

CADTH is funded by Canadian federal, provincial, and territorial governments.